Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders

Journal of Psychiatric Research

Volumn 46, Issue 8, 2012, Pages 987-993

  Koola, Maju Mathew ^a   McMahon, Robert P ^a   Wehring, Heidi J ^a   Liu, Fang ^a   Mackowick, Kristen M ^b   Warren, Kimberly R ^a   Feldman, Stephanie ^a   Shim, Joo Cheol ^c   Love, Raymond C ^a,d   Kelly, Deanna L ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c Inje University College of Medicine   (South Korea)

^d UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Alcohol; Cannabis; Mortality; Psychotic disorders; Substance use

Indexed keywords

CANNABIS;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICAL RESEARCH; MORTALITY; PRIORITY JOURNAL; PSYCHOSIS; RISK; SCHIZOPHRENIA; SUBSTANCE ABUSE; SURVIVAL;

EID: 84863473266     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.04.019     Document Type: Article

References (64)

1. Adrian M., Barry S.J. Physical and mental health problems associated with the use of alcohol and drugs. Substance Use & Misuse 2003, 38:1575-1614.
2. Agarwal D.P. Cardioprotective effects of light-moderate consumption of alcohol: a review of putative mechanisms. Alcohol and Alcoholism 2002, 37:409-415.
3. Andreasson S., Allebeck P. Cannabis and mortality among young men: a longitudinal study of Swedish conscripts. Scandinavian Journal of Social Medicine 1990, 18:9-15.
4. Aryana A., Williams M.A. Marijuana as a trigger of cardiovascular events: speculation or scientific certainty?. International Journal of Cardiology 2007, 118:141-144.
5. Beijer U., Andreasson A., Agren G., Fugelstad A. Mortality, mental disorders and addiction: a 5-year follow-up of 82 homeless men in Stockholm. Nordic Journal of Psychiatry 2007, 61:363-368.
6. Brugal M.T., Barrio G., Royuela L., Bravo M.J., de la Fuente L., Regidor E. Estimating mortality attributed to illegal drug use in Spain. Medicina Clinica (Barcelona) 2004, 123:775-777.
7. Cantor-Graae E., Nordstrom L.G., McNeil T.F. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophrenia Research 2001, 48:69-82.
8. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biological Psychiatry 2005, 57(10):1117-1127.
9. Chambers R.A., Krystal J.H., Self D.W. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biological Psychiatry 2001, 50:71-83.
10. Colton C.W., Manderscheid R.W. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Preventing Chronic Disease 2006, 3:A42.
11. Copeland L., Budd J., Robertson J.R., Elton R.A. Changing patterns in causes of death in a cohort of injecting drug users, 1980-2001. Archives of Internal Medicine 2004, 164:1214-1220.
12. Costa B., Siniscalco D., Trovato A.E., Comelli F., Sotgiu M.L., Colleoni M., et al. AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. British Journal of Pharmacology 2006, 148:1022-1032.
13. Croxford J.L., Miller S.D. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212. Journal of Clinical Investigation 2003, 111:1231-1240.
14. Cruce G., Ojehagen A. Risky use of alcohol, drugs and cigarettes in a psychosis unit: a 1 1/2 year follow-up of stability and changes after initial screening. BMC Psychiatry 2007, 7:31.
15. Dekker N., Linszen D.H., De Haan L. Reasons for cannabis use and effects of cannabis use as reported by patients with psychotic disorders. Psychopathology 2009, 42:350-360.
16. Demetriades D., Gkiokas G., Velmahos G.C., Brown C., Murray J., Noguchi T. Alcohol and illicit drugs in traumatic deaths: prevalence and association with type and severity of injuries. Journal of the American College of Surgeons 2004, 199:687-692.
17. Dickey B., Normand S.L., Weiss R.D., Drake R.E., Azeni H. Medical morbidity, mental illness, and substance use disorders. Psychiatric Services 2002, 53:861-867.
18. Dickey B., Dembling B., Azeni H., Normand S.L. Externally caused deaths for adults with substance use and mental disorders. Journal of Behavioral Health Services & Research 2004, 31:75-85.
19. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophrenia Research 1999, 35(Suppl.):S93-100.
20. Dixon L., Haas G., Weiden P.J., Sweeney J., Frances A.J. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. American Journal of Psychiatry 1991, 148:224-230.
21. Drake R.E., Osher F.C., Wallach M.A. Alcohol use and abuse in schizophrenia. A prospective community study. Journal of Nervous and Mental Disease 1989, 177:408-414.
22. Drake R.E., Rosenberg S.D., Mueser K.T. Assessing substance use disorder in persons with severe mental illness. New Directions for Mental Health Services 1996, 3-17.
23. Duke P.J., Pantelis C., Barnes T.R. South Westminster schizophrenia survey. Alcohol use and its relationship to symptoms, tardive dyskinesia and illness onset. British Journal of Psychiatry 1994, 164:630-636.
24. D'Souza D.C., Abi-Saab W.M., Madonick S., Forselius-Bielen K., Doersch A., Braley G., et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry 2005, 57:594-608.
25. Fowler I.L., Carr V.J., Carter N.T., Lewin T.J. Patterns of current and lifetime substance use in schizophrenia. Schizophrenia Bulletin 1998, 24:443-455.
26. Frisher M., Collins J., Millson D., Crome I., Croft P. Prevalence of comorbid psychiatric illness and substance misuse in primary care in England and Wales. Journal of Epidemiology and Community Health 2004, 58:1036-1041.
27. Goodman L.A., Salyers M.P., Mueser K.T., Rosenberg S.D., Swartz M., Essock S.M., et al. Recent victimization in women and men with severe mental illness: prevalence and correlates. Journal of Traumatic Stress 2001, 14:615-632.
28. Gronbaek M., Johansen D., Becker U., Hein H.O., Schnohr P., Jensen G., et al. Changes in alcohol intake and mortality: a longitudinal population-based study. Epidemiology 2004, 15:222-228.
29. Harris E.C., Barraclough B. Excess mortality of mental disorder. British Journal of Psychiatry 1998, 173:11-53.
30. Hashibe M., Straif K., Tashkin D.P., Morgenstern H., Greenland S., Zhang Z.F. Epidemiologic review of marijuana use and cancer risk. Alcohol 2005, 35:265-275.
31. Havassy B.E., Alvidrez J., Owen K.K. Comparisons of patients with comorbid psychiatric and substance use disorders: implications for treatment and service delivery. American Journal of Psychiatry 2004, 161:139-145.
32. Hoffmann D.E., Weber E. Medical marijuana and the law. New England Journal of Medicine 2010, 362:1453-1457.
33. Jockers-Scherubl M.C., Wolf T., Radzei N., Schlattmann P., Rentzsch J., Gomez-Carrillo de Castro A., et al. Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2007, 31:1054-1063.
34. Kapp C. Swiss debate whether to legalise cannabis. Alcohol and tobacco pose far greater danger, say advocates of cannabis legalisation. Lancet 2003, 362:970.
35. Kelly D.L., McMahon R.P., Liu F., Love R.C., Wehring H.J., Shim J.C., et al. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. Journal of Clinical Psychiatry 2010, 71:304-311.
36. Kelly D.L., McMahon R.P., Wehring H.J., Liu F., Mackowick K.M., Boggs D.L., et al. Cigarette smoking and mortality risk in people with schizophrenia. Schizophrenia Bulletin 2011, 37(4):832-838.
37. Kessler R.C., McGonagle K.A., Zhao S., Nelson C.B., Hughes M., Eshleman S., et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United states. Results from the national comorbidity survey. Archives of General Psychiatry 1994, 51:8-19.
38. Klatsky A.L., Friedman G.D., Armstrong M.A., Kipp H. Wine, liquor, beer, and mortality. American Journal of Epidemiology 2003, 158:585-595.
39. La Rana G., Russo R., Campolongo P., Bortolato M., Mangieri R.A., Cuomo V., et al. Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]. Journal of Pharmacology and Experimental Therapeutics 2006, 317:1365-1371.
40. Leeson V.C., Harrison I., Ron M.A., Barnes T.R., Joyce E.M. The effect of cannabis use and cognitive Reserve on age at onset and psychosis outcomes in first-episode schizophrenia. Schizophrenia Bulletin 2011.
41. Littrell K.H., Petty R.G., Hilligoss N.M., Peabody C.D., Johnson C.G. Olanzapine treatment for patients with schizophrenia and substance abuse. Journal of Substance Abuse Treatment 2001, 21:217-221.
42. Loberg E.M., Hugdahl K. Cannabis use and cognition in schizophrenia. Frontiers in Human Neuroscience 2009, 3:53.
43. MacDonald J. Medical marijuana: informational resources for family physicians. American Family Physician 2009, 80:779.
44. Malinski M.K., Sesso H.D., Lopez-Jimenez F., Buring J.E., Gaziano J.M. Alcohol consumption and cardiovascular disease mortality in hypertensive men. Archives of Internal Medicine 2004, 164:623-628.
45. Margolese H.C., Malchy L., Negrete J.C., Tempier R., Gill K. Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophrenia Research 2004, 67:157-166.
46. Maynard C., Cox G.B., Hall J., Krupski A., Stark K.D. Substance use and five-year survival in Washington State mental hospitals. Administration and Policy in Mental Health 2004, 31:339-345.
47. McCreadie R.G. Use of drugs, alcohol and tobacco by people with schizophrenia: case-control study. British Journal of Psychiatry 2002, 181:321-325.
48. Mueser K.T., Yarnold P.R., Levinson D.F., Singh H., Bellack A.S., Kee K., et al. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophrenia Bulletin 1990, 16:31-56.
49. Mukamal K.J., Conigrave K.M., Mittleman M.A., Camargo C.A., Stampfer M.J., Willett W.C., et al. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. New England Journal of Medicine 2003, 348:109-118.
50. Murray R.P., Connett J.E., Tyas S.L., Bond R., Ekuma O., Silversides C.K., et al. Alcohol volume, drinking pattern, and cardiovascular disease morbidity and mortality: is there a U-shaped function?. American Journal of Epidemiology 2002, 155:242-248.
51. Newman S.C., Bland R.C. Mortality in a cohort of patients with schizophrenia: a record linkage study. Canadian Journal of Psychiatry 1991, 36:239-245.
52. Nyhlen A., Fridell M., Backstrom M., Hesse M., Krantz P. Substance abuse and psychiatric co-morbidity as predictors of premature mortality in Swedish drug abusers: a prospective longitudinal study 1970-2006. BMC Psychiatry 2011, 11:122.
53. Ortega-Gutierrez S., Molina-Holgado E., Arevalo-Martin A., Correa F., Viso A., Lopez-Rodriguez M.L., et al. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. FASEB Journal 2005, 19:1338-1340.
54. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. Journal of American Medical Association 1990, 264:2511-2518.
55. Rosen C.S., Kuhn E., Greenbaum M.A., Drescher K.D. Substance abuse-related mortality among middle-aged male VA psychiatric patients. Psychiatric Services 2008, 59:290-296.
56. Scotter E.L., Abood M.E., Glass M. The endocannabinoid system as a target for the treatment of neurodegenerative disease. British Journal of Pharmacology 2010, 160:480-498.
57. Sidney S., Beck J.E., Tekawa I.S., Quesenberry C.P., Friedman G.D. Marijuana use and mortality. American Journal of Public Health 1997, 87:585-590.
58. Siris S.G., Kane J.M., Frechen K., Sellew A.P., Mandeli J., Fasano-Dube B. Histories of substance abuse in patients with postpsychotic depressions. Comprehensive Psychiatry 1988, 29:550-557.
59. Soyka M., Albus M., Kathmann N., Finelli A., Hofstetter S., Holzbach R., et al. Prevalence of alcohol and drug abuse in schizophrenic inpatients. European Archives of Psychiatry and Clinical Neuroscience 1993, 242:362-372.
60. Staffa J.A., Jones J.K., Gable C.B., Verspeelt J.P., Amery W.K. Risk of selected serious cardiac events among new users of antihistamines. Clinical Therapeutics 1995, 17:1062-1077.
61. Suominen K., Isometsa E., Haukka J., Lonnqvist J. Substance use and male gender as risk factors for deaths and suicide-a 5-year follow-up study after deliberate self-harm. Social Psychiatry and Psychiatric Epidemiology 2004, 39:720-724.
62. Waksman Y., Olson J.M., Carlisle S.J., Cabral G.A. The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. Journal of Pharmacology and Experimental Therapeutics 1999, 288:1357-1366.
63. Wells S., Broad J., Jackson R. Alcohol consumption and its contribution to the burden of coronary heart disease in middle-aged and older New Zealanders: a population-based case-control study. New Zealand Medical Journal 2004, 117. U793.
64. Wilkins K. Moderate alcohol consumption and heart disease. Health Reports 2002, 14:9-24.